axgt initi coverag buy ahead gene
messag like axgt diversifi approach gene therapi includ
lenti aav effort address rare monogen diseas well
larger indic parkinson view risk/reward skew heavili
upsid current level near-term clinic data updat provid opportun
inflect acknowledg compani recent volatil histori think
restructur key gene therapi rare diseas hire pipelin posit new compani
well go forward initi coverag buy rate pt
year restructur enter full steam ahead
cns/neuromuscular gene therapi focu assembl strong team made
senior leader space key hire gene therapi rare diseas
compani beyond compani spent last month build diversifi
gene therapi pipelin expect product clinic year end
see reason optim head initi data pipelin program
march axo-lenti-pd differenti local administ gene therapi parkinson
diseas think data agilis/ptct help valid aadc approach
data predecessor program follow show strong safeti
efficaci program build tradit
orphan focus gene therapi fatal pediatr diseas also local administ earli
biomark data could provid posit readthrough ultim efficaci
expect addit pipelin progress addit program enter clinic
system gene therapi treatment pediatr
progress neurolog disord per compani first patient set dose
ist nih axo-aav-opmd util local intramuscular inject aav
silenc replac defect gene restor muscl function adult-onset
neuromuscular disord expect enter clinic
end cash current cash suffici posit
compani well continu advanc pipelin toward key data readout view
page analyst certif import disclosur
clinic stage gene therapi compani develop pipelin
therapi treatment neurolog neuromuscular disord
soon known axov gene therapi ltd axov sole focu
develop gene therapi compani built pipelin clinic
preclin gene therapi candid diversifi
approach lenti aav also target market ultra-rar
near-term clinic catalyst march compani two lead
program provid first look compani new gene therapi
axo-lenti-pd lentivir approach design increas level
dopamin brain in-licens lentivir gene therapi program
oxford biomedica compani respons manufactur lentivir
vector nv kymriah june axo-lenti-pd vivo gene
therapi inject directli brain deliv three gene includ aadc
goal enabl end-to-end endogen dopamin synthesi durabl
consist level reduc motor fluctuat contrast vygr
vy-aadc deliv aadc gene thu depend
concurr levodopa dose effect current enrol trial
uk sunrise-pd patient dose
expect initi data march
first gen version shown safe well toler
initi sign efficaci lenti-pd new improv version prosavin
patient worth data follow pretti
robust data set gene therapi standard phase studi advanc
pd treatment prosavin produc averag decreas
baselin updr part score maintain
year follow-up on-going said magnitud impact seen
rang observ placebo studi result
hard interpret importantli prosavin shown safe well toler
think particular note context vivo lentivir gene
think bode well axo-lenti-pd
potent axo-lenti-pd make use vector optim
transgen deliv gene non-human primat similar efficaci
observ lower dose vs prosavin wed note lowest dose
use axo-lenti-pd program equal mid-dos use
prosavin studi think could see sign efficaci initi cohort
efficaci think substanti amount safeti data also
encourag given vector would highlight fact
fda allow includ prosavin data axo-lenti-pd ind file
pd may quintessenti gene therapi indic see
place non-cur therapi ultim success contrast
gene therapi approach aim correct underli genet
defect hope cure approach symptomat natur one
doc put clever way deliv dopamin paradigm shift term
page analyst certif import disclosur
address diseas said see place
approach even potenti conserv assumpt peak
penetr db elig patient one-tim cost get
peak revenu
aav base therapeut fatal pediatr neurolog
disord initi data also expect march includ tay-sach
diseas sandhoff diseas ultra-rar progress neurolog
lysosom storag disord caus defici hex enzym activ
axgt first aav base therapi enter clinic recent
in-licens umass also administ directli brain
util capsid deliv two differ transgen hexa hexb
goal restor normal hex enzym function think
preclin data encourag see potenti expedit regulatori
pathway given fatal natur ultra-rar pediatr diseas
addit candid expect move clinic
provid addit clinic catalyst
system base therapi treatment pediatr
progress neurolog genet disord program also come
umass first patient dose ist nih per
compani beyond expect axo-aav-opmd enter clinic
program util deliv combin dna-direct
rna interfer silenc replac defect gene
function copi restor normal muscl function patient adult-
think compani recent hire posit well continu
build reput pipelin gene therapi compani
evolv follow feb restructur manag team dr
pavan cheruvu appoint ceo part restructur built
strong team senior leader experi clinic commerci
execut particular compani made sever key hire
gene therapy/rar diseas side includ dr fraser wright formerli
co-found spark sever other experi
clinic develop manufactur commerci compani
novarti sarepta rocket pharma
end cash suffici
posit compani well continu execut pipelin
initi coverag buy rate price target base sum-
of-the-part peak revenu analysi arriv price
target util multipl peak sale estim base
geographi indic outlin gene therapi initi
appli discount line model pre-data gene therapi
compani parkinson assum peak penetr
advanc pd patient elig db one time appli
po axo-lenti-pd result remaind
pipelin model peak penetr diagnos patient cost
year assum amort model appli
po result rest valuat come
platform cash
page analyst certif import disclosur
gene therapi
compani focu
neurolog
axo-lenti-pd parkinson diseas axgt lead program lentiviral-
vector base gene therapi treatment parkinson diseas one-
shot second-gener therapi involv deliveri three gene aadc th
via partner oxb lentivector construct encod critic enzym
tyrosin hydroxylas cyclohydrolas aromat l-amino acid
decarboxylas end-to-end endogen dopamin synthesi durabl
consist level inject brain putamen gene therapi
candid design reduc motor fluctuat pd hold
world-wide exclus licens develop commerci oxb
axo-lenti-pd pd uk axgt/oxb dose second patient
sunrise-pd phase trial axo-lenti-pd novemb
schedul releas initi data march
tay-sachs/sandhoff gangliosidosi
also focus fatal pediatr neurolog neuromuscular
diseas tay-sach sandhoff gangliosidosi caus
mutat hexa lead tay-sach diseas hexb lead
sandhoff diseas gene character impair enzym function
accumul toxic gangliosid progress destroy neuron
doubl vector-bas investig gene
therapi deliv function copi hexa hexb directli
unilater icv bilater thalam infus restor hex enzym activ
address diseas first patient on-going phase clinic trial
dose accord initi data
expect
gangliosidosi preclin studi
evalu bicistron construct serotyp deliv gene hexa
hexb singl construct via system administr treatment
tay-sach sandhoff diseas
gangliosidas axgt next therapeut candid
move clinic aav-bas therapi
gangliosidosi pediatr progress neurolog genet
disord caus mutat gene lead
page analyst certif import disclosur
deficiency/reduct lysosom -galactosidas -gal enzym axo-
base therapi deliv function copi
restor -gal enzym activ treatment diseas although
current ind-en stage phase trial program expect
conduct nation institut accord compani
first patient dose expect initi data
axo-aav-opmd oculopharyng muscular dystrophi axo-aav-
opmd investig gene therapi would
administ opmd patient use cricopharyng pharyng muscl
inject opmd rare progress adult-onset neuromuscular disord
caus defect gene result aggreg misfold
protein muscl character slowli progress muscl diseas
affect muscl eyelid throat limb axo-aav-opmd
design deliv combin dna-direct rna interfer silenc
replac defect gene function copi restor
normal muscl function affect individu current late preclin stage
plan initi phase trial treat opmd patient
earli stage pipelin addit aav-medi gene therapi
earli preclin stage includ axo-aav- amyotroph later
sclerosi axo-aav-ftd frontotempor dementia along four
undisclos program may learn later year
guggenheim secur llc compani report
march expect initi data axo-lenti-pd
potenti compani march day nyc
program also continu gener data throughout year
look forward initi data program well phase
trial initi axo-aav-opmd program year also
watch progress pipelin program advanc toward
page analyst certif import disclosur
ticker drug diseas eventexpect timingpric impact potenti axonaxo-lenti-pdparkinson -dose pt initi data expect first pt dose initi data expect axon -- first pt dose initi data expect axonaxo-aav-opmdoculopharyng muscular trial initi sandhoffpreclin program develop tbalowaxonaxo-aav-alsamyotroph later sclerosispreclin program develop tbalowaxonaxo-aav-ftdfrontotempor dementiapreclin program develop tbalow
axgt approach viral vector-medi gene
focus develop gene therapi indic
see area particularli attract opportun given feasibl
target deliveri region brain broader deliveri spinal cord
durabl transgen express neuron termin differenti
immune-privileg site
lenti axgt gene therapi platform parkinson diseas program licens
oxb make use lentivir vector integr transgen
payload dna patient putamin cell vivo therebi make
perman chang in-depth review lentivir vector see
gene therapi primer
aav axgt gene therapi platform neurodegen diseas
gangliosidos oculopharyng muscular dystrophi amyotroph
later sclerosi frontotempor dementia make use adeno-associ
viral aav vector deliv therapeut gene vivo target tissu
compani licens aav vector umass medic school
aav vector opmd bntc develop commerci gene therapi
indic relat diseas background gene therapi
aav vector see gene therapi primer
pd second common chronic progress neurodegen
disord affect approxim older american adult year
preval expect rise dramat next year
american popul age idiopath diseas nervou system
character motor non-motor manifest neurodegen
disord mimic idiopath pd dementia lewi bodi
corticobas degener cbd multipl system atrophi
pd patholog defin loss degener dopamine-
produc dopaminerg neuron critic aadc enzym aromat l-amino
acid decarboxylase/dopa decarboxylas substantia nigra
develop lewi bodi patholog hallmark neuron loss
dopamin result mark impair motor control optim neuron
function also inhibit lewi bodi abnorm
intracellular aggreg contain protein alpha-synuclein
ubiquitin patholog chang may preced classic symptom pd
tremor rigid bradykinesia slow movement postur instabl
two decad underli molecular pathogenesi complex
involv multipl pathway mechan -synuclein proteostasi
transport neuroinflamm risk factor modul
mechan age averag age onset year famili histori
genet could lower age onset lifestyl exposur pesticid
high dietari intak iron exposur certain miner reliabl
page analyst certif import disclosur
predict biomark exist pd henc difficult predict onset
progress diseas well prevent neurodegener
figur substantia nigra midbrain hous dopamine-produc
neuron lost/degener due variou factor result
pd
progress loss
fiber
substantia nigra
putamen
adapt compani present
figur dopamin express lost parkinson diseas
nation institut environment health scienc nih
clinic manifest pd encompass four major compon motor
symptom cognit chang behavioral/neuropsychiatri chang
autonom nervou system-failur relat symptom variabl clinic
present larg result area affect prior
neuroimag patholog studi suggest motor function pd
patient neg alter substantia nigra neuron
degener major motor symptom tremor rest present
pd case rigid cogwheel jerk seen almost pd patient
page analyst certif import disclosur
akinesia bradykinesia postur stoop shuffl gait
pronounc advanc pd patient symptom respond least well
dopamin treatment make mnemon trap encapsul
clinic symptom pd non-motor featur may preced motor symptom
includ constip alter sens smell rem sleep disord orthostat
hypotens depress erectil dysfunct urinari incontin add
pd affect million patient world-wide repres approxim
senior adult age men like pd
women us million individu affect pd new
diagnos year mean age death regardless age
pd onset qualiti diseas manag
current treatment pd aim address dopamin deficit inappropri
dopamine/oth neurotransmitt imbal control symptom though
address underli pathophysiolog process motor
symptom interfer everyday life patient drug one three
firstlin drug class levodopa better efficaci dopamin agonist
monoamine-oxidase-b inhibitor start commerci l-dopa combin
two drug levodopa carbidopa mainstay current treatment
diseas carbidopa ad levodopa prevent breakdown
levodopa cross brain carbidopa cross
blood-brain barrier bbb addit carbidopa allow lower dose
levodopa use combin drug taken oral levodopa
cross bbb convert dopamin brain improv
nerv conduct assist movement disord parkinson diseas
late pd oral medic supplement drug deliveri via altern
therapi aim improv overal dopaminerg function
figur treatment option initi symptomat therapi pd
mechan action
degre
risk side effect
dopamin precursor cross blood
brain barrier convert
dopamin dopaminerg termin
stimul
receptor block receptor
receptor
page analyst certif import disclosur
select irrevers inhibit mao-
 inhibit presynapt dopamin
receptor dopamin uptak
revers inhibit comt
blockad muscarin cholinerg
receptor possibl inhibit
cholinerg transmiss striatal
lack
lack
lack
non-select block action
epinephrin norepinephrin
adrenerg receptor
lack
lack
lack
increas synthesi releas
lack
lack
lack
adapt clark ce bmj janic mb frontier bioscienc
despit wide use l-dopa treat pd diseas steadili worsen
time motor non-motor aspect signific unmet need exist
treat patient includ wane efficaci time fluctuat
state dyskinesia motor fluctuat
manifest alter good control period pd
symptomat period advanc pd patient becom increasingli less
respons oral l-dopa therapi requir higher dose manag
symptom patient experi longer period reduc mobil stiff
term off-tim time medic longer provid benefit
shorter period on-tim medic effect
figur chang levodopa respons time on/off fluctuat
page analyst certif import disclosur
per year approxim patient time patient develop
on-off motor fluctuat start levodopa therapi ldopa
pharmacokinet continu degener dopamine-contain neuron
chang dopamin receptor signal thought
underli caus patient experi decreas effect
intervent may advoc involv surgic implant
electrod brain provid continu high frequenc electr stimul
reduc pd symptom approxim pd patient experi
motor fluctuat oral levodopa due cours diseas progress opt
db procedur provid good candid surgeri per
kol post-hoc analysi standard motor score pilot trial
particip conduct vanderbilt univers medic center reveal
possibl db slow rest tremor progress earli pd patient
patient standard-of-car drug therapi develop rest tremor
previous unaffect limb cours two-year studi period
occur patient receiv db therapi addit
drug therapi
db effect requir extens pre-op test
contraind pd patient evid cognit impair
dementia develop nation averag lifespan continu
increas econom human burden may prove substanti
prosavin pd
prosavin oxb gene therapi candid treatment parkinson
diseas therapi design deliv construct three gene th
aadc encod critic enzym requir biochem
synthesi dopamin endogen tyrosin
tyrosin hydroxylas th enzym catalyz convers
tyrosin levodopa l-dopa unlik enzym th protein
enzymat activ strictli control rate-limit step
dopamin biosynthesi th express level activ directli
involv regul intracellular dopamin level activ th
modul two mechan medium- long-term regul
gene express increas enzym stabil transcript
rna stabil gene edit short-term regul enzym activ
feedback inhibit alloster regul phosphoryl
cyclohydrolas rate-limit enzym synthesi
tetrahydrobiopterin critic cofactor product l-dopa
requir enzymat activ th loss-of-funct
mutat gene result sever reduct dopamin
synthesi nigrostriat cell common caus
dopa-respons dystonia drd rare diseas classic
present childhood gener dystonia dramat long-
last respons levodopa
page analyst certif import disclosur
aromat l-amino acid decarboxylas aadc enzym
convert l-dopa dopamin decarboxyl ldopa aadc
control step format dopamin parkinsonian
patient alter enzym activ regul might contribut
decreas therapeut respons ldopa
figur three gene crucial dopamin synthesi pathway
figur vector configur prosavin
adapt oxb/axgt poster
figur prosavin vs l-dopa effect dopamin releas
page analyst certif import disclosur
preclin experi prosavin oxb demonstr long-term
safeti therapeut dose therapi well signific efficaci
improv measur movement reduc dyskinesia nhp model
specif prosavin safe restor striatal dopamin product
normal correct motor deficit without associ dyskinesia p-valu
prosavin improv pd symptom clinic diseas sever
nhp model durabl respons seen month one
prosavin-tr nhp continu studi exhibit sustain motor
improv studi conclud month
figur rate dyskinesia lower preclin nhp model treat
prosavin
nonclin studi data reveal advers event find
potenti impact safeti provid pertin data optim method
deliveri clinic prosavin also found well toler co-
administ l-dopa apomorphin indic use
conjunct standard care pd medic
trial design oxb evalu prosavin safeti efficaci phase
studi patient advanc pd uk franc primari
endpoint includ number sever advers event sae well
updr part score month drug administr four
patient cohort evalu three dose level prosavin
cohort dose level two mid tu
page analyst certif import disclosur
therapi deliv striatum patient bilater idiopath pd
use stereotact inject modifi deliveri method administr
introduc cohort increas rate deliveri enhanc
distribut vector modifi deliveri method includ chang
l/min reduct diamet cannula gaug
five needl track five depot three needl track
figur clinic design prosavin phase studi
oxb poster present esgct
efficaci therapi assess sustain improv motor
function measur unifi parkinson diseas rate scale
updr part motor score state levodopa medic
oxb/axgt refer updr part qualiti life assess
use parkinson diseas questionnair everi month
year yearli thereaft open-label follow-up
efficaci updr wide use comprehens
assess tool motor non-motor symptom associ
parkinson diseas made six differ section score rang
item part normal sever score
item part iv irregular item score absenc he/sh
wit other refer durat intens total
score subscal part point part ii part part iv
therefor updr total score rang point part
ii score interview part score structur
neurolog examin score part iv base interview
observ ideal repeat rate done time
day time last dose medic rater
page analyst certif import disclosur
activ daili life speech swallow handwrit dress hygien
fall level saliv walk freez walk cut food
turn bed adjust bed cloth tremor sensori complaint relat
parkinson
rest action postur tremor hand rigid finger tap hand
movement rapid altern movement hand leg agil aris
chair postur gait postur stabil bodi bradykinesia hypokinesia
complic dopaminerg therapi dyskinesia clinic fluctuat
period complic
hoehn yahr stage progression/sever diseas stage
combin featur motor impair disabl
schwab england activ daili life scale
adapt pd resourc theracycl
phase prosavin studi updr assess perform
practic defin state follow overnight drug withdraw across
patient mean updr part score significantli improv
compar baselin
figur mean improv updr part motor score
baselin point observ patient month
sustain improv observ six year follow-up
long-term follow-up studi still on-going year exposur earliest
page analyst certif import disclosur
figur pd patient treat prosavin durabl benefit updr part
score observ
treat patient continu receiv oral l-dopa therapi obtain maxim
benefit went receiv db year post-prosavin patient
receiv db differ time point post prosavin dose per palfi et al
addit overal magnitud effect within rang report
placebo studi arm clinic trial pd use surgic
intervent compar shorter time frame also difficult assess
dose respons given small sampl popul patient attrit
observ follow-up period studi
patient-report questionnair assess pd-
specif health-rel qualiti preced month questionnair
assess often patient experi difficulti across qualiti life
dimens mobil activ daili live emot well-b
stigma social support cognit commun bodili comfort
point ordin score system never occasion sometim
often alway dimens total score rang never
difficulti alway difficulti lower score repres better qualiti
life dimens score sum score item dimens divid
maximum possibl score item dimens multipli
overal score summar parkinson diseas summari
pdsi summari si sum dimens
total score divid
patient diari data phase prosavin studi suggest decreas
mean time spent unrespons medic state
increas respons medic without dyskinesia state
patient overal differ dose cohort report
respect measur
safeti sae relat prosavin surgic procedur report
report gener mild relat either pd progress l-
dopa-induc dyskinesia amelior reduct l-dopa
administr common first month dyskinesia
on-off motor fluctuat headach akinesia immun
respons report cohort low-level antibodi respons
vsv-g envelop protein detect patient three
four patient antibodi protein part gag protein make
viral particl observ observ consist preclin
page analyst certif import disclosur
axo-lenti-pd re-
tailor enhanc
product putamen
deliv th aadc
gene putamen
brain enabl neuron
express three critic
enzym encod
gene amelior
symptom parkinson
studi anti-vsv-g respons seen rat non-human
primat similar preclin studi vector antibodi respons give
rise inflammatori respons patient assess sequenti brain
mri deterior clinic state overal safeti profil
similar across dose cohort
axo-lenti-pd pd
axgt lead therapeut candid pd axo-lenti-pd formerli
licens june oxb exclus develop global
commerci lenti-vir gene therapi diseas condit axo-
lenti-pd gener version prosavin util lentivir vector
system enabl larg gene packag capac allow deliveri
multipl transgen product multifactori experiment
modifi transgen prosavin improv endogen dopamin product
differ order gene
fusion th flexibl linker
remov genet control element th aadc
figur vector configur comparison prosavin axo-lenti-pd
believ chang lead balanc stoichiometri
gene express coloc enzymat activ deliveri
three gene aim drive continu increas endogen
synthesi dopamin region brain pd patient goal
therapi offer less troublesom dyskinesia less time
time lower requir exogen l-dopa pd patient
target net result dopamin product transduc
cell vivo compar prosavin without impact infus volum
rate administr axo-lenti-pd deliv one-tim mri-guid
stereotact infus putamen
page analyst certif import disclosur
figur goal axo-lenti-pd provid elev durabl dopamin
synthesi brain pd patient
axgt/oxb vitro experi axo-lenti-pd demonstr
fold increas dopamin l-dopa product prosavin
figur axo-lenti-pd achiev higher increas dopamin
levodopa product vs prosavin primari human neuron vitro preclin
vivo experi non-human primat model show dose-depend
increas aadc activ brain axo-lenti-pd compar prosavin
measur pet scan month function nhp model
dose axo-lenti-pd demonstr similar level improv
spontan locomotor activ compar prosavin
page analyst certif import disclosur
figur axo-lenti-pd achiev higher aadc activ level brain nhp
model month compar prosavin aadc activ visual
believ data provid evid axo-lenti-pd greater
potenc compar prosavin term dopamin product enzymat
activ function improv anim model parkinson diseas
initi phase clinic studi axo-lenti-pd patient
bilater idiopath pd octob expect initi clinic data
march studi design consist two part
part non-random dose-escal multipl potenti dose
part double-blind design patient random either activ
group receiv optim dose determin part control group
receiv imit sham surgic procedur
studi evalu safeti toler axo-lenti-pd well
assess efficaci use clinic measur motor function unifi
page analyst certif import disclosur
parkinson diseas rate scale updr part patient diari
biomark axo-lenti-pd deliv one-tim mri-guid
stereotact infus putamen
figur sunrise-pd phase trial design evalu safeti toler part safeti efficaci part
axo-lenti-pd patient parkinson diseas
part singl administr differ dose axo-lenti-pd striatum brain
part either select dose therapi part imit surgic procedur bilater skin incis control
time-fram month follow paramet measur chang baselin
safeti axo-lenti-pd measur incid teae sae assess nation cancer institut common
terminolog criteria advers event ctcae sever
safeti measur chang clinic laboratori analysi
safeti measur chang vital sign
safeti measur chang brain mri find
safeti measur chang physic examin
time-fram month follow paramet measur chang baselin
chang updr score defin medic state
chang motor fluctuat assess patient diari
chang dyskinesia rate scale
elig patient age year diagnos bilater idiopath pd least year time surgeri
presenc motor fluctuat and/or dyskinet movement
candid surgic intervent
hoehn yahr stage medic state
stabl dose pd medic includ l-dopa four week prior screen
histori psychosi current treatment dopamin block agent prior regular exposur antipsychot agent
histori stereotact surgeri treatment pd includ deep brain stimul db
current anticip treatment anticoagul therapi use anticoagul therapi
temporarili stop around time surgeri
diagnosi multipl system atrophi
abnorm mri find mega cisterna septum pellucidum sign sever cortic subcort atrophi
brain tumor vascular diseas trauma arterioven malform
presenc dementia
clinicaltri gov guggenheim secur llc
first patient dose octob initi interim data expect
vygr advanc clinic candid vy-aadc gene therapi
treatment parkinson diseas evalu open-label phase
clinic trial dose first pd patient phase
trial decemb vy-aadc compris capsid
cmv promot drive aadc transgen express enabl neuron
page analyst certif import disclosur
axgt direct competitor
pd whose
aadc phase
putamen express aadc enzym convert levodopa dopamin
deliv directli putamen
complet dose patient phase clinic trial continu
monitor result trial show durabl dose-depend time-
depend improv across multipl measur patient motor function
timepoint report one-tim administr gene therapi
result includ data patient treat cohort five
patient cohort includ data patient cohort three year
cohort two year cohort month
cohort patient receiv singl administr vy-aadc total
dose vg
cohort patient receiv singl administr vy-aadc total
dose vg
cohort patient receiv vy-aadc total dose
vy-aadc treatment result increas increas
increas mean putamin aadc enzym activ cohort
respect six month rel baselin measur f-dopa pet
scan coverag putamen aadc enzym activ highli
correl addit one-tim administr vy-aadc
result reduc daili dose oral levodopa relat medic
includ mean reduct baselin cohort month
mean reduct baselin cohort two year
increas baselin low-dos cohort three year recent
updat long-term data novemb studi also includ
mean improv good time baselin three year
patient cohort mean improv baselin year
cohort mean improv hour baselin eighteen
month cohort
phase trial conduct phase trial vy-
aadc gene therapi assess distribut efficaci safeti vy-aadc
patient pd motor fluctuat feedback type
meet fda decemb discuss overal develop
program vy-aadc plan submit revis trial protocol
includ increas target enrol phase trial
result total patient trial conduct staggered-parallel
phase trial similar size design
statu part strateg develop commerci collabor
fund clinic develop phase pivot program
vy-aadc plan begin enrol patient activ addit
global trial site anticip month enrol period
data readout phase trial would
option either co-commerci vy-aadc
cost- profit-shar arrang receiv mileston royalti
base ex-u sale grant full global commerci right
exchang mileston payment royalti base global sale
expect updat enrol statu year
page analyst certif import disclosur
ptct lead gene therapi candid ptc-aadc anoth aav gene therapi
deliv aadc gene treatment aadc defici children
rare disord involv loss aadc gene function therapi
assess two clinic trial one trial on-going administr
ptc-aadc similar axo-lenti-pd vy-aadc one-tim dose
ptc-aadc putamen reduc risk off-target uptak secret
excret gene therapi liver kidney result prior two
complet trial suggest patient may gain motor function
improv cognit scale follow ptc-aadc administr
demonstr signific increas motor function contrast
publish natur histori ptc-aadc evalu efficaci
aadc defici patient differ indic pd thu
competit view
mgtx investig gene therapi program aav-gad phase trial
design deliv glutam acid decarboxylas gad gene subthalam
nucleu increas product gamma-aminobutyr acid gaba
primari inhibitori neurotransmitt human brain gad rate-limit
enzym synthesi gaba therefor believ increas
gad express subthalam nucleu gene therapi
result normal motor circuit mechan similar db
improv symptom pd patient without affect brain region
respons complic exist therapi aav-gad ad
mgtx pipelin acquir vector neurosci prior phase
clinic trial aav-gad termin due financi reason
random double-blind sham-control trial mgtx aav-gad
receiv track design fda
prevail gene therapi pipelin target parkinson diseas
lysosom dysfunct disord use technolog
partnership pd stage unclear prevail focus develop
gene therapi target glucocerebrosidas gene earli
figur gene therapi landscap parkinson diseas
clinicaltri gov compani report guggenheim secur llc
page analyst certif import disclosur
companytickerdiseasedrugmechanismrout admin transgenevectorphasenext eventexpect timingaxov sciencesaxon parkinson diseaseaxo-lenti-pdlentivir gene therapyintracrani striatumth aadclentivectorphas pt initi data expect march voyag therapeuticsvygradvanc parkinson diseasevy-aadcaav gene therapyintracranial- term data therapeuticsvygradvanc parkinson diseasevy-aadcaav gene therapyintracranial- enrol therapeuticsvygradvanc parkinson diseasevy-aadcaav gene therapyintracranial- enrol diseaseaav-gadaav gene therapi subthalam nucleusgad-phas initiationtbaprevail therapeuticsprivateparkinson diseasen/aaav gene therapi
rare lysosom
storag disord
monogen defect
gangliosidosi also known land diseas rare autosom
recess fatal pediatr diseas caus prematur death
character toxic build-up gangliosid due defect
gene lead impair -galactosidas -gal enzym activ
build-up gangliosid tissu particularli result
neurodegener cognit impair paralysi life expect
shorten two four year age sever form
figur gene therapi target gangliosidosi
base age onset categor three main type
type early-onset rapidli progress form start
month may utero life expect year
type ii subdivid infantil juvenil late-onset form
late-onset infantil form symptom appear
year life expect year
symptom juvenil form begin age
learn plateau motor cognit regress life
expect year
type adult form later onset character
sever diseas correl level -gal activ clinic
represent vari includ arrest/regress neurolog
coars facial featur cardiomyopathi
incid estim birth
world-wide birth us eu preval
patient us eu per nih type appear
common form diseas
current treatment landscap high unmet need
current treatment landscap symptomat support life
expect short note caus death includ
pneumonia due recurr aspir cardiopulmonari failur due
page analyst certif import disclosur
reason signific unmet need cur therapi
gangliosidosi
licens umass medic school develop
commerci therapi global treatment exchang
develop regulatori commerci mileston school axo-aav-
investig gene therapi gangliosidosi design
restor -galactosidas function introduc function copi
gene aav vector gene therapi candid util
neurotrop vector known cross blood brain barrier
effici transduc neuron especi infant vector encod gene
-gal control promot increas enzym express
investig therapi design one-tim system administr via
intraven infus take advantag high vascular
also aim treat peripher manifest diseas
figur gene therapi
preclin studi mous model gene therapi
candid found partial rescu -gal activ peripher
organ week post iv dose vg/kg ld vg/kg
hd vector rel gal activ wt cerebrum cerebellum
brainstem mice dose sex depend
part normal level -gal activ dramat elev
liver heart muscl serum male femal mice
impact lysosom storag appear modest thalamu striatum
purkinj cell layer complet clearanc storag seen
dorsal cochlear nucleu dcn reduct lysosom storag materi
brain spinal cord mark femal mice
male may partli due lower liver-trop femal mice
result higher effici gene transfer behavior function
remain stabl longer lifespan significantli increas aav-
treat cohort may result therapeut impact spinal
cord normal content resolut
page analyst certif import disclosur
figur improv -gal activ peripher organ
reduc gangliosid burden low high dose administ
intraven week age
studi success extend surviv mice arrest
diseas progress dose test eventu anim
develop whole bodi tremor jerki movement may relat
margin therapeut impact cerebellum diseas progress
cerebellar nuclei cell popul
nonetheless replic mous studi felin demonstr
improv neuromuscular function normal brain architectur year
age felin treat vg/kg
intraven week age
page analyst certif import disclosur
figur felin achiev improv neuromuscular function normal brain
architectur post-treat
dose first patient iv dose vg/kg
nih outcom measur includ safeti clinic rate
score brain atrophi naa level csf serum -gal level behavior
score neurocognit score walk test immun respons per axgt nih
assembl larg natur histori databas diseas progress
patient could serv histor control group clinic
initi clinic data trial expect
continu enrol patient program year
best knowledg current investig gene therapi exist
clinic could compet howev lys-fr
program preclin develop includ
page analyst certif import disclosur
treatment gangliosidosi lys-fr agre
strateg collabor umm auburn univers develop
ind-support preclin studi use aav gene therapi technolog
compani also secur brammer suppli industrial-scal
manufactur therapi clinic test clinic trial site select
trial current on-going trial expect launch year
accord compani passagebio also preclin stage gene
therapi expect clinic
tay-sach rare autosom recess neurodegen diseas
result defici beta-hexosaminidas enzym sever
diseas directli correl deplet enzym
distinguish gener age onset categor
infantil common sever form symptom occur
first month life diseas fatal earli childhood
juvenil rang sever symptom appear age
diseas fatal teenag year
late onset/adult least sever form symptom appear late
childhood adulthood lifespan may shorten remain
symptom rang loss learn skill seizur loss muscl mental
function behavior problem gradual loss skill frequent respiratori
infect psychiatr disord need mobil assist
mutat hexa gene lead tay-sach diseas hexb gene
lead sandhoff diseas encod two subunit
hexosaminidas hex enzym caus dysfunct defici beta-
hex enzym requir digest gangliosid lipid healthi
child enter nerv cell sourc energi lipid left
undigest defici ineffici hex-a enzym accumul
neuron bodi caus diseas symptom shorten life
expect year age
tay-sach sandhoff
diseas rare lipid
storag disord
monogen defect well-
mutat hexa gene
mutat hexb gene
page analyst certif import disclosur
figur hexa hexb gene therapi target gangliosidosi
incid tay-sachs/sandhoff diseas estim birth
world-wide birth us eu preval
patient us eu per
current treatment unmet need
treatment cure slow childhood form tay-
sach symptomat treatment like anti-seizur medicin provid support
form diseas henc signific need
transform medicin
tay-sach sandhoff diseas
licens umass medic school develop
commerci therapi global treatment exchang
develop regulatori commerci mileston school axo-aav-
investig gene therapi gangliosidosi aim
restor hex function introduc function copi hexa hexb
page analyst certif import disclosur
figur gene therapi tay-sach sandhoff diseas
therapi uniqu co-deliv two vector ratio
deliv hexa hexb gene maxim hex format report
deliv either transgen alon suffici bring compar
efficaci serotyp effici transduc neuron low
immunogen plan perform one-tim intracrani bilater
thalam unilater icv infus one procedur intent
reduc chanc immun reaction direct-to-cn
preclin studi sandhoff diseas mous model
perform umm high dose gene therapi vg/kg show
signific elev hex activ gangliosid clearanc
brain median surviv mice also increas compar wild-
figur high dose gene therapi significantli increas hex
activ clearanc brain sandhoff diseas mous model
significantli increas median surviv treat mice
page analyst certif import disclosur
evalu safeti efficaci phase trial
nih outcom measur safeti csf biomark hex
per axgt similar program nih assembl larg natur
histori databas diseas progress patient could serv
histor control group clinic trial
first patient dose novemb dose vg/kg
initi data expect march per addit patient
continu enrol throughout year
best knowledg current investig gene therapi exist
could compet
opmd slowli progress muscular diseas inherit
primarili autosom domin pattern diseas gener present
patient age year old character primarili
progress difficulti swallow dysphagia eyelid droop ptosi
weak proxim extrem swallow difficulti life-
threat consequ includ malnutrit aspir pneumonia
diseas progress swallow difficulti becom sever
muscl may becom involv includ weak wast atrophi
tongu patient may also doubl vision diplopia frequent
weak muscl near center bodi
page analyst certif import disclosur
opmd caus mutat gene code ubiquit
express protein regul process mrna normal
protein contain ten copi amino acid alanin form
polyalanin tract opmd mutat gene expans
alanine-encod trinucleotid repeat result abnorm long
polyalanin tract protein form mutat gene prone
aggreg insolubl nuclear inclus bodi lead muscl cell
patholog diseas progress
figur characterist symptom opmd
opmd patient symptom
abnorm pharynx
merrf syndrom clump diseas mitochondria
accumul subsarcolemm region muscl fiber
small area focal destruct muscl fiber
spinal disord vertebra slip forward onto
bone underneath
opmd patient symptom
gard nih guggenheim secur llc
per opmd estim affect approxim peopl
north america europ accord genet diseas
inform center nih autosom domin form opmd
common among ethnic jewish popul israel incid
opmd also affect individu french-canadian ancestri
peopl franc autosom recess form carrier opmd
affect peopl franc quebec japan
current treatment opmd symptomat support sever droop
eyelid ptosi may treat plastic surgeri eyelid
blepharoplasti rais eyelid affect individu see
individu sever difficulti swallow dysphagia may surgic
procedur known cricopharyng myotomi cricopharyng
muscl throat cut swallow occur muscl remain
page analyst certif import disclosur
take interest
approach silenc
replac method gene
silenc tackl silenc
wild-typ mutant
gene caus
opmd dna-
relax allow passag food liquid orthoped devic
cane leg brace walker assist individu difficulti walk
despit specif intervent support treatment address
symptom opmd provid relief patient recurr symptom
commonli occur year intervent current cur
treatment progress muscl diseas
axo-aav-opmd opmd
axgt axo-aav-opmd formerli program investig one-
time gene therapi opmd compani licens bntc juli
gene therapi util aav vector deliv axgt silence-and-
replac construct silenc mutant poly-a bind protein
gene caus opmd replac function normal copi
gene silence-and-replac approach aim knock
express wild-typ mutant gene ddrnai
dna-direct rna interfer time express re-
engin copi resist silenc code
function protein axo-aav-opmd design deliv
singl administr directli target muscl tissu provid long-term
correct muscl patholog restor function
gene silenc mediat dna-direct rna interfer ddrnai
benefit
combin rnai gene therapi deliveri
long term therapeut potenti singl administr
constant durabl level shrna express
silenc singl gene target multipl gene simultan
simultan silenc disease-caus gene co-express
normal gene restor function
page analyst certif import disclosur
